The vector of anti-HER2×EGFR chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human HER2 and EGFR. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-HER2 antibody linked to CD3ζ signaling domain, and scFv of anti-EGFR antibody linked to CD28 and ICOS signaling domains. And the vector product was designed for the treatment of glioblastoma.
For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
Angiotensin-converting Enzyme 2 (ACE2)-CHO Cell Line Model for COVID-19: Helps researchers to further study the interaction between the receptor ACE2 and the COVID-19 virus.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE